Claims
- 1. An immunogenic peptide selected from the group consisting of SEQ ID NO.:1, SEQ ID NO.:2, SEQ ID NO.:3, and SEQ ID NO.:4.
- 2. An immunogenic composition comprising a peptide of claim 1 in a pharmaceutically acceptable carrier.
- 3. An immunogenic polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:1, SEQ ID NO.:2, SEQ ID NO.:3, and SEQ ID NO.:4.
- 4. An immunogenic composition comprising a polypeptide of claim 3 in a pharmaceutically acceptable carrier.
- 5. An isolated nucleic acid encoding an immunogenic peptide selected from the group consisting of SEQ ID NO.:1, SEQ ID NO.:2, SEQ ID NO.:3, and SEQ ID NO.:4.
- 6. A composition comprising a nucleic acid of claim 5 in a pharmaceutically acceptable carrier.
- 7. An isolated nucleic acid encoding an immunogenic peptide selected from the group consisting of:
- 8. A composition comprising a nucleic acid of claim 7 in a pharmaceutically acceptable carrier.
- 9. An expression vector comprising a nucleic acid sequence encoding an immunogenic peptide selected from the group consisting of SEQ ID NO.: 1, SEQ ID NO.:2, SEQ ID NO.:3, and SEQ ID NO.:4.
- 10. The expression vector of claim 9 wherein the vector is a plasmid or a viral vector.
- 11. The expression vector of claim 10 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
- 12. The expression vector of claim 11 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
- 13. The expression vector of claim 12 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
- 14. An expression vector comprising a nucleic acid sequence encoding an immunogenic peptide selected from the group consisting of:
- 15. The expression vector of claim 14 wherein the vector is a plasmid or a viral vector.
- 16. The expression vector of claim 15 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
- 17. The expression vector of claim 16 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
- 18. The expression vector of claim 17 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
- 19. A composition comprising an expression vector of claim 7 or 14 in a pharmaceutically acceptable carrier.
- 20. A method for preventing or treating cancer comprising administering to a host a peptide of claim 1.
- 21. A method for preventing or treating cancer comprising administering to a host a polypeptide of claim 3.
- 22. A method for preventing or treating cancer comprising administering to a host an expression vector of claim 7.
- 23. A method for preventing or treating cancer comprising administering to a host an expression of claim 14.
- 24. A host cell comprising a peptide selected from the group consisting of SEQ ID NO.:1, SEQ ID NO.:2, SEQ ID NO.:3, and SEQ ID NO.:4.
- 25. A method for preventing or treating cancer comprising administering to a patient a host cell of claim 23.
- 26. A method for inducing an immune response in a patient comprising:
a) obtaining autologous cells from said patient; b) pulsing said cells in vitro with a peptide selected from the group consisting of SEQ ID NO.:1, SEQ ID NO.:2, SEQ ID NO.:3, and SEQ ID NO.:4; and, c) administering the cells of step b to said patient.
- 27. A method for inducing an immune response in a patient comprising:
a) obtaining autologous cells from said patient; b) transfecting said cells in vitro with a nucleic acid encoding a peptide selected from the group consisting of SEQ ID NO.: 1, SEQ ID NO.:2, SEQ ID NO.:3, and SEQ ID NO.:4; and, c) administering the cells of step b to said patient.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Ser. No. 60/292,590 filed May 23, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60292590 |
May 2001 |
US |